Ekso Bionics (EKSO) Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ekso Bionics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" EKSO shares.
View EKSO analyst ratings or view top-rated stocks.

1 Wall Street research analysts have issued 1 year target prices for Ekso Bionics' stock. Their EKSO share price forecasts range from $9.00 to $9.00. On average, they predict the company's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 1,204.3% from the stock's current price.
View analysts price targets for EKSO or view top-rated stocks among Wall Street analysts.

Ekso Bionics' stock was trading at $1.19 at the beginning of the year. Since then, EKSO shares have decreased by 42.0% and is now trading at $0.69.
View the best growth stocks for 2023 here.

Ekso Bionics saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 36,100 shares, an increase of 32.7% from the August 15th total of 27,200 shares. Based on an average daily trading volume, of 51,700 shares, the short-interest ratio is currently 0.7 days. Approximately 0.3% of the shares of the company are short sold.
View Ekso Bionics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our EKSO earnings forecast.

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) released its quarterly earnings results on Thursday, July, 27th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.03. The company had revenue of $4.70 million for the quarter, compared to analyst estimates of $4.35 million. Ekso Bionics had a negative net margin of 102.52% and a negative trailing twelve-month return on equity of 69.14%.

Ekso Bionics shares reverse split before market open on Thursday, May 5th 2016. The 1-7 reverse split was announced on Wednesday, May 4th 2016. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 4th 2016. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ekso Bionics investors own include Organigram (OGI), Gran Tierra Energy (GTE), KushCo (KSHB), CNBX Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), Novan (NOVN), Pennsylvania Real Estate Investment Trust (PEI) and ADMA Biologics (ADMA).

Ekso Bionics trades on the NASDAQ under the ticker symbol "EKSO."

Ekso Bionics' stock is owned by a number of retail and institutional investors. Top institutional investors include Citadel Advisors LLC (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Jason C Jones, Jerome Wong, John Glenn, Scott G Davis and Steven Sherman.
View institutional ownership trends.

Shares of EKSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EKSO stock can currently be purchased for approximately $0.69.

Ekso Bionics (NASDAQ:EKSO) has a market capitalization of $9.53 million and generates $15.71 million in revenue each year. The company earns $-15,080,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis.

Ekso Bionics' mailing address is 1414 HARBOUR WAY SOUTH SUITE 1201, RICHMOND CA, 94804. The official website for the company is www.eksobionics.com. The company can be reached via phone at (510) 984-1761, via email at investors@eksobionics.com, or via fax at 510-927-2647.